Chester County News and Community Website
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) reported fourth-quarter and full-year 2025 financial results, citing nearly $1 billion in annual net sales for its drug Rezdiffra and outlining pipeline …
Madrigal Pharmaceuticals Reports 2025 Financial Results Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) granted equity inducement awards to five newly hired non-executive employees on February 15, 2026, the company announced.
Madrigal Grants Inducement Awards to Five Employees Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) announced it has entered into an exclusive global license agreement with Suzhou Ribo Life Science Co. Ltd. and its subsidiary Ribocure Pharmaceuticals …
Madrigal Pharmaceuticals Signs Global siRNA Licensing Deal With Ribo Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) said it granted equity awards to 21 newly hired non-executive employees in early February, a move the company described as an inducement …
Madrigal Grants Equity to New Hires as MASH Drug Momentum Builds Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) said it will release its fourth-quarter and full-year 2025 financial results before U.S. markets open on Thursday, February 19, 2026, setting the …
Madrigal Sets Date to Reveal 2025 Results as Investors Watch Closely Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) has awarded equity inducement grants to 40 newly hired, non-executive employees, signaling continued workforce expansion as the company advances its approved liver disease …
Madrigal Grants Equity to 40 New Hires as MASH Drug Push Accelerates Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) has granted a substantial equity inducement award to its newly appointed chief accounting officer, signaling confidence in leadership continuity as the drugmaker advances …
Madrigal Taps New Accounting Chief With Six-Figure Equity Bet Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) moved to tighten its grip on one of biotech’s hottest disease areas, striking a $50.00 million licensing deal with Pfizer that could …
Madrigal’s $50M Pfizer Deal Sparks a New MASH Drug Power Play Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) said it granted equity inducement awards to four newly hired non-executive employees, a move that highlights the company’s effort to attract talent …
Madrigal Uses Equity Incentives to Lure Talent as MASH Drug Scales Up Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) said it will present at the J.P. Morgan Annual Healthcare Conference on Monday, January 12, 2026, placing the company before investors at …
Madrigal Heads to JPMorgan as MASH Drug Puts Company in the Spotlight Read More